LY2157299 as Treatment for Patients with Advanced HCC

March 21, 2014
Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta receptor I (TGF-β1) kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta receptor I (TGF-β1) kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Clinical Pearls:

  • The study evaluated outcomes based on drops in alpha-fetoprotein (AFP)
  • AFP is an associated marker with HCC, but not a prognostic or predictive marker
  • The median survival was just shy of 6 months for the whole population, but the data for the patients who showed the biggest drop in AFP showed an overall survival of nearly 2 years
  • TGF-β1 is an important target in HCC and needs to be studied further